Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.

To determine whether a 48-week course of amprenavir-based antiretroviral therapy is associated with metabolic alterations, 14 clinically stable human immunodeficiency virus (HIV)-infected, protease inhibitor-naive adults initiated amprenavir-based triple therapy. Twelve subjects (86%) achieved HIV RNA levels of <400 copies/mL at week 24. Fasting glucose and insulin levels did not change. Insulin sensitivity did not decrease in the first 24 weeks, but a trend toward a decrease appeared at week 48. Six subjects experienced onset or worsening of glucose tolerance by week 24. Levels of fasting triglycerides and low-density lipoprotein, high-density lipoprotein, and total cholesterol increased. Bone mineral content, lean tissue, total fat, trunk fat, limb fat, and the ratio of trunk to limb fat increased at week 48. Amprenavir-based therapy was associated with increases in serum lipid levels but no short-term decrease in insulin sensitivity. A trend toward insulin resistance appeared late in the study following weight gain, particularly of trunk fat, but without loss of limb fat.

[1]  Nader Rifai,et al.  Handbook of Lipoprotein Testing , 2001 .

[2]  T. Buchanan,et al.  Prospective Evaluation of the Effect of Initiating Indinavir‐Based Therapy on Insulin Sensitivity and B‐Cell Function in HIV‐Infected Patients , 2001, Journal of acquired immune deficiency syndromes.

[3]  K. Yarasheski,et al.  Insulin resistance in HIV protease inhibitor-associated diabetes. , 1999, Journal of acquired immune deficiency syndromes.

[4]  M. Schambelan,et al.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study , 2002, AIDS.

[5]  B Clotet,et al.  Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile , 2001, AIDS.

[6]  F. Goebel,et al.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patients , 1998, AIDS.

[7]  D. Musher,et al.  Severe Diabetes Associated with Protease Inhibitor Therapy , 1997, Annals of Internal Medicine.

[8]  M. Dubé.  Disorders of glucose metabolism in patients infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Schambelan,et al.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. , 2000 .

[10]  Ignacio Conget,et al.  Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study , 2001, The Lancet.

[11]  W. K. Henry,et al.  Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Schambelan,et al.  Metabolic effects of indinavir in healthy HIV-seronegative men , 2001, AIDS.

[13]  R. D'Agostino,et al.  Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[15]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[16]  M. Engelgau,et al.  Screening for type 2 diabetes. , 2000, Diabetes care.

[17]  R. Steigbigel,et al.  Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV Lipodystrophy , 2000, Journal of acquired immune deficiency syndromes.

[18]  R. D'Agostino,et al.  Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  R. Krauss,et al.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.

[20]  D. Cooper,et al.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.

[21]  E. Furfine,et al.  HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. , 2000, Antiviral research.

[22]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[23]  R. Bergman,et al.  Repeatability of Insulin Sensitivity and Glucose Effectiveness From the Minimal Model: Implications for Study Design , 1994, Diabetes.

[24]  J. Currier,et al.  Protease inhibitor-associated hyperglycaemia , 1997, The Lancet.

[25]  L. Duvillard,et al.  HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[26]  R. Bergman,et al.  Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. , 1981, The Journal of clinical investigation.

[27]  E. Furfine,et al.  Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice. , 2000, The Journal of nutrition.

[28]  J. Otvos,et al.  Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. , 2002, Clinical laboratory.

[29]  O. Rouvière,et al.  Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study , 2000, AIDS.

[30]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[31]  J. Leonard,et al.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.